However, due to the emergence of novel antidiabetic drugs such as Sodium-Glucose Co-Transporter 2 inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA), the current pharmacological treatment for T2DM has many differences from that used in the ACCORD study. Here, GLP1R is linked to type 2 diabetes mellitus.